BerandaBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
$55,93
Setelah Jam Perdagangan Normal:(0,00%)0,00
$55,93
Tutup: 28 Nov, 13.45.54 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$55,52
Rentang hari
$55,03 - $56,05
Rentang tahun
$50,76 - $73,51
Kapitalisasi pasar
10,74Â M USD
Volume Rata-Rata
3,20Â jt
Rasio P/E
20,96
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 776,13Â jt | 4,08% |
Biaya operasional | 682,74Â jt | 53,98% |
Penghasilan bersih | -30,74Â jt | -128,98% |
Margin laba bersih | -3,96 | -127,85% |
Penghasilan per saham | 0,12 | -86,81% |
EBITDA | -28,20Â jt | -121,22% |
Tarif pajak efektif | -16,79% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,48Â M | 58,83% |
Total aset | 7,61Â M | 11,15% |
Total liabilitas | 1,56Â M | 8,37% |
Total ekuitas | 6,06 M | — |
Saham yang beredar | 192,11 jt | — |
Harga terhadap nilai buku | 1,76 | — |
Tingkat pengembalian aset | -1,55% | — |
Tingkat pengembalian modal | -1,76% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -30,74Â jt | -128,98% |
Kas dari operasi | 368,68Â jt | 66,46% |
Kas dari investasi | -330,96Â jt | -1.948,42% |
Kas dari pembiayaan | -2,17Â jt | 99,57% |
Perubahan kas bersih | 36,29Â jt | 112,23% |
Arus kas bebas | 114,03Â jt | -31,13% |
Tentang
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Didirikan
Mar 1997
Kantor pusat
Situs
Karyawan
3.040
